Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa

Completed

• Conditions: Hidradenitis Suppurativa (HS)

• Registration Number: NCT03894956
• Lead Sponsor: AbbVie

Brief Summary

The objective of this study is to evaluate the long-term safety and effectiveness of Humira in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2019-03-27
• Study First Submitted QC: 2019-03-27
• Study First Posted: 2019-03-29
• Study Start: 2019-05-02
• Primary Completion: 2021-11-10
• Study Completion: 2021-11-10
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-01
• Last Update Posted: 2022-11-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

• Participants who have been prescribed Humira by their treating physician as per routine clinical practice for the treatment of HS.

Read More

Exclusion Criteria

• Participants previously treated with Humira.
• Participants who do not provide consent.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of participants who reported any adverse drug reactions (ADRs) during the study	Up to Week 52	ADRs will be coded by Medical Dictionary for Regulatory Activities (MedDRA) dictionary.
Percentage of participants who reported any serious infections during the study	Up to Week 52	Percentage of participants with incidence of serious infections are reported.
Percentage of participants who reported any infections during the study	Up to Week 52	Percentage of participants with incidence of infections are reported.

Secondary Outcome Measures

Name	Time	Method
Change in C-Reactive Protein (CRP)	From Baseline to Week 52	CRP values are measured as an inflammatory parameter. Low CRP values mean less inflammation.
Percentage of participants achieving "Improved" of overall improvement by physician	Up to Week 52	Percentage of participants achieving overall improvement (improved, unchanged, impossible to evaluate) is assessed by physician.
Change in Dermatology Life Quality Index (DLQI)	From Baseline to Week 52	DLQI is a 10-question validated dermatologic disease questionnaire to measure quality of life.
Percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR)	Up to week 52	HiSCR is defined as at least 50% reduction in the number of abscesses and inflammatory nodules and no increase in abscess count and no increase in draining fistula count relative to baseline.
Change in Patient's global assessment of skin pain	From Baseline to Week 52	Patient's global assessment of skin pain is evaluated on a 11-point scale with 0 for "no pain" and 10 for "worst skin pain imaginable."

Trial Locations

Locations (37)

Anjou Kousei Hospital /ID# 216741; 🇯🇵 Anjo-shi, Aichi, Japan

Kimitsu Chuo Hospital /ID# 214733; 🇯🇵 Kisarazu-shi, Chiba, Japan

NHO Nagoya Medical Center /ID# 214406; 🇯🇵 Nagoya-shi, Aichi, Japan

Nagoya University Hospital /ID# 214135; 🇯🇵 Nagoyashi, Aichi, Japan

Ehime University Hospital /ID# 214090; 🇯🇵 Toon-shi, Ehime, Japan

Kyushu University Hospital /ID# 214092; 🇯🇵 Fukuoka-shi, Fukuoka, Japan

Hospital of the University of Occupational and Environmental Health, Japan /ID# 214137; 🇯🇵 Kitakyushu-shi, Fukuoka, Japan

JA Hiroshima General Hospital /ID# 213472; 🇯🇵 Hatsukaichi-shi, Hiroshima, Japan

Sapporo Higashi Tokushukai Hospital /ID# 213865; 🇯🇵 Sapporo-shi, Hokkaido, Japan

Kobe University Hospital /ID# 215642; 🇯🇵 Kobe-shi, Hyogo, Japan

Takarazuka City Hospital /ID# 214088; 🇯🇵 Takarazuka-shi, Hyogo, Japan

Yokosuka Kyosai Hospital /ID# 215310; 🇯🇵 Yokosuka-shi, Kanagawa, Japan

Mito Kyodo General Hospital /ID# 214089; 🇯🇵 Mito-shi, Ibaraki, Japan

Yokohama City University Medical Center /ID# 216740; 🇯🇵 Yokohama shi, Kanagawa, Japan

Kochi Medical School Hospital /ID# 214091; 🇯🇵 Nankoku-shi, Kochi, Japan

Yokkaichi Municipal Hospital /ID# 215641; 🇯🇵 Yokkaichi-shi, Mie, Japan

University of the Ryukyus Hospital /ID# 214136; 🇯🇵 Nakagami-gun, Okinawa, Japan

Okayama University Hospital /ID# 215317; 🇯🇵 Okayama-shi, Okayama, Japan

Kishiwada City Hospital /ID# 213471; 🇯🇵 Kishiwada-shi, Osaka, Japan

Kindai University Hospital /ID# 217831; 🇯🇵 Osakasayama-shi, Osaka, Japan

Saitama Medical Center /ID# 218639; 🇯🇵 Kawagoe-shi, Saitama, Japan

JA Shizuoka Kohseiren Ensh Hospital /ID# 218160; 🇯🇵 Hamamatsu-shi, Shizuoka, Japan

Shizuoka City Shizuoka Hospital /ID# 217292; 🇯🇵 Shizuoka-shi, Shizuoka, Japan

Toranomon Hospital /ID# 213470; 🇯🇵 Minato-ku, Tokyo, Japan

Japan Community Health care Organization Tokyo Yamate Medical Center /ID# 214134; 🇯🇵 Shinjuku-ku, Tokyo, Japan

Japanese Red Cross Kitami Hospital /ID# 214085; 🇯🇵 Hokkaido, Japan

Toyama University Hospital /ID# 214407; 🇯🇵 Toyama-shi, Toyama, Japan

Ichinomiya Municipal Hospital /ID# 214086; 🇯🇵 Ichinomiya-shi, Aichi, Japan

Aichi Medical University Hospital /ID# 215312; 🇯🇵 Nagakute-shi, Aichi, Japan

Kyoto University Hospital /ID# 215315; 🇯🇵 Kyoto-shi, Kyoto, Japan

Bito Dermatology Clinic /ID# 215316; 🇯🇵 Kobe-shi, Hyogo, Japan

Tohoku University Hospital /ID# 217830; 🇯🇵 Sendai-shi, Miyagi, Japan

Nara Hospital Kinki University Faculty of Medicine, /ID# 218640; 🇯🇵 Ikoma-shi, Nara, Japan

Tohoku Rosai Hospital /ID# 214084; 🇯🇵 Sendai-shi, Miyagi, Japan

Osaka Medical and Pharmaceutical University Hospital /ID# 214087; 🇯🇵 Takatsuki-shi, Osaka, Japan

Saitama Medical University Hospital /ID# 215599; 🇯🇵 Iruma-gun, Saitama, Japan

Osaka University Hospital /ID# 215314; 🇯🇵 Suita-shi, Osaka, Japan